|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM040405443 |
| 003 |
DE-627 |
| 005 |
20231221151035.0 |
| 007 |
tu |
| 008 |
231221s1985 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0135.xml
|
| 035 |
|
|
|a (DE-627)NLM040405443
|
| 035 |
|
|
|a (NLM)4059298
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a d'Ambrosio, G
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Effects of combined treatment with triletide and cimetidine in gastric and duodenal ulcer patients, and a retrospective comparison with cimetidine alone
|
| 264 |
|
1 |
|c 1985
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.12.1985
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A study was carried out in 15 patients with gastric or duodenal ulcer to assess whether the efficacy of the antisecretory agent cimetidine might be improved by the addition of a cyto-protective agent, triletide, to the treatment regimen. The patients were treated for an average of 11 +/- 5 days with 0.2 g parenteral cimetidine per day plus 1.5 g oral triletide per day. Endoscopy was performed before and after treatment, as well as routine haematology and haematochemistry. Intensity of symptoms and signs of the illness was scored and recorded daily during the first 5 days of treatment, as well as the extent of antacid intake. Collected data were compared with those of a series of 15 superimposable patients who had shortly before been treated with 0.2 g/day of cimetidine alone. A greater proportion of patients given the combination was found to be endoscopically healed after treatment in comparison with those who had cimetidine alone (53% vs 40%). Intensity of symptoms decreased significantly faster and to a significantly greater extent in the same patients, as did antacid intake. The intensity of objective signs (tenderness, melaena) showed a similar but not significantly different trend. Total symptom intensity decreased twice as fast with the combination in comparison with cimetidine alone (time to decrease by 50%: 4.2 days vs 8.2, respectively). There was no evidence of side-effects or intolerance during treatment
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Anti-Ulcer Agents
|2 NLM
|
| 650 |
|
7 |
|a Oligopeptides
|2 NLM
|
| 650 |
|
7 |
|a triletide
|2 NLM
|
| 650 |
|
7 |
|a 50Q6LI773L
|2 NLM
|
| 650 |
|
7 |
|a Cimetidine
|2 NLM
|
| 650 |
|
7 |
|a 80061L1WGD
|2 NLM
|
| 700 |
1 |
|
|a d'Annabile, A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 4(1985), 3 Spec No vom: 15., Seite 171-6
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:4
|g year:1985
|g number:3 Spec No
|g day:15
|g pages:171-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 4
|j 1985
|e 3 Spec No
|b 15
|h 171-6
|